Efficacy of prolonged ingestion of Lactobacillus acidophilus L-92 in adult patients with atopic dermatitis.
To evaluate the safety and efficacy of prolonged ingestion of Lactobacillus acidophilus L-92 (L-92) on skin symptoms in adult atopic dermatitis (AD) patients, a placebo-controlled double-blinded parallel-group comparison study was performed. This included daily administration of heat-killed and dried L-92 or placebo for 24wk in 50 AD patients who were 16yr old or older. The severity of skin symptoms was evaluated at baseline and at 4, 8, 12, 16, 20, and 24wk during the intervention using the investigator global assessment, eczema area and severity index, and scoring atopic dermatitis. Serum cytokine and blood marker levels were also measured at baseline and at 4, 8, 16, and 24wk during the intervention. No adverse events were reported during the study period. Compared with the placebo group, the L-92 group showed significant decreases in investigator global assessment, eczema area and severity index, and scoring atopic dermatitis. Subjective symptoms in adult AD patients were reduced by intake of L-92. Furthermore, it was suggested that sustained ingestion of L-92 resulted in suppression of scratching behavior and maintenance of remission status of skin symptoms. Sixteen weeks after the study commenced, a significant decrease in lactate dehydrogenase and a significant increase in transforming growth factor-β were observed in the L-92 group compared with the placebo group. In the L-92 group, a significant elevation of IL-12 (p70) level at the end of treatment period compared with before the treatment was observed. This study suggested that L-92 suppresses type-2-helper-T-cell-dominant inflammation by activating regulatory T cells and type 1 helper T cells.
Department of Epidemiology and Environmental Health, Juntendo University Faculty of Medicine, Tokyo 113-8421, Japan. Electronic address: kzyamamo@juntendo.ac.jp.
Kozo
K
Yamamoto
Department of Epidemiology and Environmental Health, Juntendo University Faculty of Medicine, Tokyo 113-8421, Japan.
Kazuhito
K
Yokoyama
Department of Epidemiology and Environmental Health, Juntendo University Faculty of Medicine, Tokyo 113-8421, Japan.
Takehisa
T
Matsukawa
Microbiology & Fermentation Laboratory, Asahi Group Holdings Ltd., Kanagawa 252-0206, Japan.
Sayaka
S
Kato
Microbiology & Fermentation Laboratory, Asahi Group Holdings Ltd., Kanagawa 252-0206, Japan.
Shinji
S
Kato
Microbiology & Fermentation Laboratory, Asahi Group Holdings Ltd., Kanagawa 252-0206, Japan.
Kazuhisa
K
Yamada
Microbiology & Fermentation Laboratory, Asahi Group Holdings Ltd., Kanagawa 252-0206, Japan.
Tatsuhiko
T
Hirota
D000293:Adolescent; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000032:analysis; D016207:Cytokines / Q000187:drug effects*; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000382:microbiology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007564:Japan; D007779:Lactobacillus acidophilus / Q000737:chemistry*; D008297:Male; D008875:Middle Aged; D019936:Probiotics / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
D015415:Biomarkers; D016207:Cytokines
Lactobacillus acidophilus; allergy; atopic dermatitis; placebo-controlled double-blinded parallel-group comparison study